These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36342143)

  • 21. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension.
    Gradman AH; Brady WE; Gazdick LP; Lyle P; Zeldin RK
    Clin Ther; 2002 Jul; 24(7):1049-61. PubMed ID: 12182251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
    Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
    Clin Ther; 2010 Jul; 32(7):1252-69. PubMed ID: 20678674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
    Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.
    Weber MA; Black H; Bakris G; Krum H; Linas S; Weiss R; Linseman JV; Wiens BL; Warren MS; Lindholm LH
    Lancet; 2009 Oct; 374(9699):1423-31. PubMed ID: 19748665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
    Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study.
    Hong SJ; Jeong HS; Han SH; Chang KY; Hong BK; Lee BK; Chae SC; Kim WS; Park CG; Heo JH; Lee SU; Kim YD; Kim KS; Choi JH; Kang HJ; Kim JJ; Kang SM; Choi YJ; Shin JH; Chun KJ; Shin DG; Park SH; Kwan J; Choi YJ; Jeong MH; Chae JK; Kim DW; Cho JR; Han KR; Won KH; Park SH; Lee SK; Kim SH; Jung J; Kim CH
    Clin Ther; 2017 Oct; 39(10):2049-2060. PubMed ID: 28939406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
    Lee HY; Kim YJ; Ahn T; Youn HJ; Chull Chae S; Seog Seo H; Kim KS; Rhee MY; Choi DJ; Kim JJ; Chun KJ; Yoo BS; Park JS; Oh SK; Kim DS; Kwan J; Ahn Y; Bae Park J; Jeong JO; Hyon MS; Cho EJ; Han KR; Kim DI; Joo SJ; Shin JH; Sung KC; Jeon ES
    Clin Ther; 2015 Nov; 37(11):2581-2596.e3. PubMed ID: 25850881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.
    Hong SJ; Ahn TH; Baek SH; Cho WH; Jeon HK; Kwan J; Yoon MH; Lee KJ; Lim DS
    Clin Ther; 2006 Apr; 28(4):537-51. PubMed ID: 16750465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
    Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function.
    Freeman MW; Halvorsen YD; Bond M; Murphy B; Isaacsohn J
    Clin Pharmacol Drug Dev; 2024 Apr; 13(4):410-418. PubMed ID: 38311833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
    Williams B; MacDonald TM; Morant S; Webb DJ; Sever P; McInnes G; Ford I; Cruickshank JK; Caulfield MJ; Salsbury J; Mackenzie I; Padmanabhan S; Brown MJ;
    Lancet; 2015 Nov; 386(10008):2059-2068. PubMed ID: 26414968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors.
    Feldman JM; Frishman WH; Aronow WS
    Cardiol Rev; 2024 Feb; ():. PubMed ID: 38358268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension.
    Volpe M; Junren Z; Maxwell T; Rodriguez A; Gamboa R; Gomez-Fernandez P; Ortega-Gonzalez G; Matadamas N; Rodriguez F; Dass B; Kyle C; Clarysse L; Bryce A; Moreno-Heredia E; Germano G; Gilles L; Smith RD; Sanderson JE;
    Clin Ther; 2003 May; 25(5):1469-89. PubMed ID: 12867222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group.
    Lacourcière Y; Pool JL; Svetkey L; Gradman AH; Larochelle P; de Champlain J; Smith WB
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):454-61. PubMed ID: 9607384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
    Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
    Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial.
    Na SH; Lee HY; Hong Baek S; Jeon HK; Kang JH; Kim YN; Park CG; Ryu JK; Rhee MY; Kim MH; Hong TJ; Choi DJ; Cho SW; Cha DH; Jeon ES; Kim JJ; Shin JH; Park SH; Lee SH; John SH; Shin ES; Kim NH; Lee SY; Kwan J; Jeong MH; Kim SW; Jeong JO; Kim DW; Lee NH; Park WJ; Ahn JC; Won KH; Uk Lee S; Cho JH; Kim SK; Ahn T; Hong S; Yoo SY; Kim SY; Kim BS; Juhn JH; Kim SY; Lee YJ; Oh BH
    Clin Ther; 2015 Aug; 37(8):1726-39. PubMed ID: 26164786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.